Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of dovitinib in solid tumors
2014-000368-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in Non-hematologic malignancy, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability. Started Mar 2014; status: completed.
02
Drugs
dovitinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2014-000368-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000368-17.